GlassScriptPhysician profile
Robert P Hudec
NPI 1497745467
$4,333.33
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $441 · 2021: $568 · 2022: $856 · 2023: $693 · 2024: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $865.20 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $439.93 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $359.11 | 2019-2024 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $305.88 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.38 | 2019-2024 | Jardiance |
| Pfizer INC. | $248.69 | 2019-2024 | |
| Abbvie INC. | $207.07 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.12 | 2019-2022 | |
| Amarin Pharma, INC. | $135.46 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $131.67 | 2021-2024 | Rexulti |
| Dexcom, INC. | $122.21 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $115.12 | 2019-2023 | |
| Astellas Pharma US INC | $94.47 | 2019-2024 | Veozah |
| Abbott Laboratories | $93.24 | 2020-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $86.26 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $76.75 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $74.81 | 2019-2023 | Lagevrio, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $70.61 | 2022 | |
| Sanofi-Aventis U.S. LLC | $56.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.10 | 2022-2023 | |
| Glaxosmithkline, LLC. | $50.33 | 2019-2023 | Arexvy |
| Eisai INC. | $36.52 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.31 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $28.31 | 2021 | |
| Sumitomo Pharma America, INC. | $26.18 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $26.16 | 2020-2022 | |
| Shire North American Group INC | $19.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.64 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Medtronic USA, INC. | $13.78 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.00 | 2021 | |
| Sanofi Pasteur INC. | $12.61 | 2020 | |
| Esperion Therapeutics, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hudec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.